Back to Search
PHILIP ARLEN, PHD
PHD
Specialist
NPI: 1841182078Individual
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
Research & Publications (20)
Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts.
PMID 18505806·Infect Immun·2008
7-preclinical
Field production and functional evaluation of chloroplast-derived interferon-alpha2b.
PMID 17490449·Plant Biotechnol J·2007
8-other
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
PMID 19495750·Cancer Immunol Immunother·2010
8-other
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
PMID 19235596·Cancer Invest·2009
3-trial
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
PMID 19451403·J Clin Pharmacol·2009
3-trial
Promising novel immunotherapies and combinations for prostate cancer.
PMID 19284377·Future Oncol·2009
6-review
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
PMID 19167733·J Urol·2009
2-rct
Cancer vaccines: current directions and perspectives in prostate cancer.
PMID 19169957·Curr Opin Mol Ther·2009
6-review
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
PMID 19548854·Expert Opin Investig Drugs·2009
6-review
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
PMID 19154507·BJU Int·2009
3-trial
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
PMID 18628467·Clin Cancer Res·2008
3-trial
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
PMID 18698048·Clin Cancer Res·2008
3-trial
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
PMID 18710748·J Urol·2008
3-trial
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
PMID 18483372·Clin Cancer Res·2008
5-case
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
PMID 18172272·Clin Cancer Res·2008
3-trial
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.
PMID 18281535·Clin Cancer Res·2008
8-other
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
PMID 18423743·J Urol·2008
6-review
Therapeutic prostate cancer vaccines: a review of the latest developments.
PMID 19037836·Curr Opin Investig Drugs·2008
6-review
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
PMID 18197807·Crit Rev Immunol·2007
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1120 NW 14TH ST
MIAMI, FL 33136 - Phone
- (305) 243-5247
Quick Facts
- NPI
- 1841182078
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile